Analyse REGENXBIO Inc. (RGNX) — Kairos Score 65/100

À propos de REGENXBIO Inc.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Informations clés

🕴️ Activité des initiés (90 jours)

5 transactions — 2 achats et 0 ventes déclarés par les dirigeants de REGENXBIO Inc..

🏦 Hedge Funds

17 fonds institutionnels déclarent une position sur RGNX dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur RGNX.

• Regenxbio’s Two Lead Gene Therapies Back Mizuho’s Nearly 200% Upside Call
• Regenxbio stock gains on positive gene therapy trial data

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.